NHAS
CRNX

Novo Holdings A/S’s Crinetics Pharmaceuticals CRNX Stock Holding History

Novo Holdings A/S’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.4M Sell
1,320,000
-230,000
-15% -$8.55M 2.87% 11
2026
Q1 		$56.3M Sell
1,550,000
-75,000
-5% -$3.35M 4.56% 7
2025
Q4 		$75.6M Hold
1,625,000
– – 5.87% 6
2025
Q3 		$67.7M Buy
1,625,000
+75,000
+5% +$2.4M 4.36% 8
2025
Q2 		$44.6M Buy
1,550,000
+275,000
+22% +$8.49M 3.15% 9
2025
Q1 		$42.8M Buy
1,275,000
+314,785
+33% +$11.8M 3.25% 10
2024
Q4 		$49.1M Sell
960,215
-39,785
-4% -$2.23M 2.97% 11
2024
Q3 		$51.1M Hold
1,000,000
– – 2.54% 13
2024
Q2 		$44.8M Sell
1,000,000
-98,600
-9% -$4.55M 2.41% 11
2024
Q1 		$51.4M Sell
1,098,600
-1,400
-0.1% -$54.8K 3.55% 7
2023
Q4 		$39.1M Hold
1,100,000
– – 2.42% 16
2023
Q3 		$32.7M Hold
1,100,000
– – 2.42% 18
2023
Q2 		$19.8M Hold
1,100,000
– – 1.53% 24
2023
Q1 		$17.7M Buy
1,100,000
+362,943
+49% +$6.72M 1.17% 25
2022
Q4 		$13.5M Buy
737,057
+105,430
+17% +$1.86M 0.84% 34
2022
Q3 		$12.4M Hold
631,627
– – 0.59% 30
2022
Q2 		$11.8M Buy
631,627
+206,730
+49% +$4.13M 0.58% 32
2022
Q1 		$9.33M Buy
+424,897
New +$8.6M 0.49% 37
2021
Q2 		– Sell
-271,378
Closed -$4.15M – 56
2021
Q1 		$4.15M Hold
271,378
– – 0.17% 46
2020
Q4 		$3.83M Hold
271,378
– – 0.16% 43
2020
Q3 		$4.25M Buy
271,378
+56,925
+27% +$870K 0.21% 41
2020
Q2 		$3.76M Buy
214,453
+50,000
+30% +$852K 0.24% 32
2020
Q1 		$2.42M Buy
164,453
+29,444
+22% +$603K 0.16% 28
2019
Q4 		$3.39M Hold
135,009
– – 0.22% 24
2019
Q3 		$2.03M Hold
135,009
– – 0.35% 25
2019
Q2 		$3.38M Hold
135,009
– – 0.47% 25
2019
Q1 		$3.07M Hold
135,009
– – 0.45% 20
2018
Q4 		$4.05M Sell
135,009
-14,991
-10% -$422K 0.57% 20
2018
Q3 		$4.3M Buy
+150,000
New +$4.45M 0.34% 21

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Novo Holdings A/S's CRNX Position: Q2 2026 in Review

Novo Holdings A/S reduced its Crinetics Pharmaceuticals (CRNX) stake by 15% in Q2 2026, selling an estimated $8.55M and leaving 1,320,000 shares worth $49.4M. The position accounts for 2.87% of the portfolio, ranked #11.

Novo Holdings A/S first reported a position in CRNX in Q3 2018 and has held it in 29 quarters since. The position peaked at $75.6M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Novo Holdings A/S held 1,320,000 shares of Crinetics Pharmaceuticals worth $49.4M as of Q2 2026.
  • Novo Holdings A/S sold 230,000 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $8.55M.
  • Crinetics Pharmaceuticals made up 2.87% of Novo Holdings A/S's portfolio in Q2 2026, its #11 holding.
  • Novo Holdings A/S first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 29 quarters since.
  • Novo Holdings A/S's Crinetics Pharmaceuticals position peaked at $75.6M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.